Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) Sees Significant Increase in Short Interest

Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) saw a significant growth in short interest in March. As of March 31st, there was short interest totalling 64,500 shares, a growth of 78.7% from the March 15th total of 36,100 shares. Approximately 2.6% of the company’s shares are short sold. Based on an average trading volume of 109,900 shares, the days-to-cover ratio is presently 0.6 days.

Creative Medical Technology Price Performance

Shares of CELZ traded up $0.01 during midday trading on Thursday, hitting $1.99. The stock had a trading volume of 41,789 shares, compared to its average volume of 47,271. The company has a 50 day simple moving average of $3.49 and a two-hundred day simple moving average of $3.11. Creative Medical Technology has a twelve month low of $1.69 and a twelve month high of $6.90. The firm has a market cap of $3.48 million, a price-to-earnings ratio of -0.52 and a beta of 2.00.

Institutional Investors Weigh In On Creative Medical Technology

An institutional investor recently bought a new position in Creative Medical Technology stock. Geode Capital Management LLC purchased a new stake in Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,308 shares of the company’s stock, valued at approximately $25,000. Geode Capital Management LLC owned approximately 0.59% of Creative Medical Technology as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 1.42% of the company’s stock.

About Creative Medical Technology

Creative Medical Technology Holdings, Inc, a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease.